نتایج جستجو برای: chemotherapy regimen

تعداد نتایج: 152947  

2014
Frédéric Fiteni Marine Jary Franck Monnien Thierry Nguyen Eric Beohou Martin Demarchi Erion Dobi Francine Fein Denis Cleau Serge Fratté Virginie Nerich Franck Bonnetain Xavier Pivot Christophe Borg Stefano Kim

BACKGROUND Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimens have shown efficacy in phase II trials and there is no comparative study between differ...

2015
Alessandro Bittoni Michela Del Prete Mario Scartozzi Mirco Pistelli Riccardo Giampieri Luca Faloppi Maristella Bianconi Stefano Cascinu

The definition of the standard chemotherapy regimen for advanced gastric cancer is still a matter of debate. Aim of our analysis was to retrospectively assess whether an intensive, three-drugs, front line approach could be comparable to a sequential (two-drugs front line then second line) in terms of RR (response rate), PFS (progression free survival) and OS (overall survival) in advanced gastr...

2016
Shuliang Liu Hongji Yang Xingping Ge Lingfei Su Aifeng Zhang Liang Liang

The aim of the study was to examine the drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer (NSCLC). In total, 156 NSCLC patients without surgical treatment were selected, including 117 cases of adenocarcinoma (75%), to receive single gefitinib 0.25 g/day or combined with platinum chemotherapy. Computed tomography was used to evaluate tumor growth for the respon...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
J R Kroep M Ouali H Gelderblom A Le Cesne T J A Dekker M Van Glabbeke P C W Hogendoorn P Hohenberger

BACKGROUND the role of chemotherapy in advanced malignant peripheral nerve sheath tumor (MPNST) is unclear. PATIENTS AND METHODS chemotherapy-naive soft tissue sarcomas (STS) patients treated on 12 pooled nonrandomized and randomized European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials were retrospectively analyzed. Clinical outcomes, overall su...

2017
Hyun Joo Jang Bum Jun Kim Jung Han Kim Hyeong Su Kim

Bevacizumab has shown survival benefits when added to chemotherapy in patients with metastatic colon cancer (mCRC). However, the efficacy of bevacizumab may depend on the accompanying chemotherapeutic regimen. We performed this meta-analysis to examine the impact of the choice of chemotherapy regimen on the survival benefits of bevacizumab in the first-line treatment for patients with mCRC. Ele...

2011
Hisato Igarashi Tetsuhide Ito Terumasa Hisano Nao Fujimori Yusuke Niina Mikihiko Yasuda Toyoma Kaku Susumu Matsuo Takamasa Oono Masahiro Yoshinaga Hiroyuki Sakai Ryoichi Takayanagi

BACKGROUND/OBJECTIVES Gemcitabine (GEM) is a gold-standard chemotherapy agent for advanced pancreatic cancer. Because of the malignant character of the disease, nearly all patients show disease progression despite treatment with GEM-based chemotherapy; therefore, second-line chemotherapy may be beneficial for these patients. We report a retrospective analysis of 5 patients with advanced pancrea...

2009
J. Gaulin R. Kotb E. Turcotte G. Berard B. Sawan G. Schmutz P. Beauregard

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI...

Journal: :international journal of hematology-oncology and stem cell research 0
zohreh sanaat hematology & oncology research center, tabriz university of medical sciences, tabriz ,iran. reza khalili hematology & oncology research center, tabriz university of medical sciences, tabriz ,iran. shohreh almasi immunology research center, tabriz university of medical sciences, tabriz, iran. mohammad reza aliparasti hematology & oncology research center, tabriz university of medical sciences, tabriz ,iran. seyed-mohammad tavangar pathology department, shariati hospital, tehran university of medical science, tehran, iran. aliakbar movasaghpoor hematology & oncology research center, tabriz university of medical sciences, tabriz ,iran.

introduction: acute myeloid leukemia is a malignant transformation of hematopoietic tissue, bone marrow infiltration of undifferentiated cells known as blasts that interfere with the production of normal cells. vascular endothelial growth factor (vegf) is persistently secreted from myeloid cells and high levels can be detected in patients' serum. methods: twenty-one aml patients, who were chemo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید